Form4insider filings, from the source

SEC Form 5 · accession 0001209191-17-010870

Lineage Cell Therapeutics, Inc. · LCTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Judith Segall
Officer — Vice President & Secretary
Period of report
Dec 31, 2016
Accepted (ET)
Feb 14, 2017 · 7:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Shares, no par valueF1,F2Apr 6, 2016G1,900$3.25D591,245D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Option to Purchase Common SharesF3$2.50holding————Jan 19, 2026Common Shares25,00025,000D
Option to Purchase Common SharesF4$4.23holding————Mar 2, 2025Common Shares50,00050,000D
Option to Purchase Common SharesF5$3.51holding————Mar 19, 2021Common Shares50,00050,000D
Option to Purchase Common SharesF6$4.22holding————Feb 19, 2020Common Shares50,00050,000D

Explanation of responses